{"id":"https://openalex.org/W4394444648","doi":"https://doi.org/10.6084/m9.figshare.24249424","title":"Supplementary Material for: Cystoid macular edema following treatment with nanoparticle albumin-bound paclitaxel and atezolizumab for metastatic breast cancer","display_name":"Supplementary Material for: Cystoid macular edema following treatment with nanoparticle albumin-bound paclitaxel and atezolizumab for metastatic breast cancer","publication_year":2023,"publication_date":"2023-01-01","ids":{"openalex":"https://openalex.org/W4394444648","doi":"https://doi.org/10.6084/m9.figshare.24249424"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/24249424","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Cystoid_macular_edema_following_treatment_with_nanoparticle_albumin-bound_paclitaxel_and_atezolizumab_for_metastatic_breast_cancer/24249424","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Cystoid_macular_edema_following_treatment_with_nanoparticle_albumin-bound_paclitaxel_and_atezolizumab_for_metastatic_breast_cancer/24249424","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"H., Yamane","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H., Yamane","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"T., Itagaki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T., Itagaki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057822473","display_name":"Keiko Kajitani","orcid":"https://orcid.org/0000-0002-7160-9193","observed_orcids":["https://orcid.org/0000-0002-7160-9193"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K., Kajitani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073951694","display_name":"Yuji Koura","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y., Koura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113535892","display_name":"Yoshiharu Kawabuchi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y., Kawabuchi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5040303815","display_name":"Masahiro Ohara","orcid":"https://orcid.org/0000-0003-4174-5052","observed_orcids":["https://orcid.org/0000-0003-4174-5052"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M., Ohara","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13467","display_name":"Drug-Induced Ocular Toxicity","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T13467","display_name":"Drug-Induced Ocular Toxicity","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11328","display_name":"Ocular Oncology and Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cystoid-macular-edema","display_name":"cystoid macular edema","score":1.0},{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9990000128746033},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9710000157356262},{"id":"https://openalex.org/keywords/chemotherapy-induced-ocular-toxicity","display_name":"chemotherapy-induced ocular toxicity","score":0.7620000243186951},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.3930000066757202}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.8750027418136597},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6727977395057678},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.6500542759895325},{"id":"https://openalex.org/C2780347916","wikidata":"https://www.wikidata.org/wiki/Q1813737","display_name":"Macular edema","level":3,"score":0.6165807843208313},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5030505061149597},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49549543857574463},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.44343048334121704},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38564103841781616},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3680349886417389},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.32110774517059326},{"id":"https://openalex.org/C2778257484","wikidata":"https://www.wikidata.org/wiki/Q555066","display_name":"Visual acuity","level":2,"score":0.10116788744926453},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.08089664578437805},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:figshare.com:article/24249424","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Cystoid_macular_edema_following_treatment_with_nanoparticle_albumin-bound_paclitaxel_and_atezolizumab_for_metastatic_breast_cancer/24249424","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.24249424","doi":"https://doi.org/10.6084/m9.figshare.24249424","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.24249424","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.24249424.v1","doi":"https://doi.org/10.6084/m9.figshare.24249424.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.24249424.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/24249424","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Cystoid_macular_edema_following_treatment_with_nanoparticle_albumin-bound_paclitaxel_and_atezolizumab_for_metastatic_breast_cancer/24249424","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4387664685","https://openalex.org/W2166652777","https://openalex.org/W2025102265","https://openalex.org/W1564296953","https://openalex.org/W4200188089","https://openalex.org/W7098142114","https://openalex.org/W4413685720","https://openalex.org/W2300931630","https://openalex.org/W4286208403","https://openalex.org/W2019523791"],"abstract_inverted_index":{"Cystoid":[0],"macular":[1],"edema":[2],"(CME)":[3],"is":[4],"a":[5,52,107],"rare":[6],"side":[7,124],"effect":[8],"associated":[9],"with":[10,24,37,39,62,70],"chemotherapy.":[11],"Although":[12,94],"the":[13,33,49,74,122],"development":[14],"of":[15,35,51,101,121],"CME":[16,36,57,111],"has":[17,41,103,112],"been":[18,44,115],"reported":[19],"to":[20],"occur":[21],"following":[22],"treatment":[23,38,109,129],"taxane":[25],"drugs,":[26],"such":[27],"as":[28],"nanoparticle":[29],"albumin-bound":[30],"paclitaxel":[31],"(Nab-PTX),":[32],"occurrence":[34],"atezolizumab":[40,80],"not":[42,68,113],"yet":[43,114],"reported.":[45],"Here,":[46],"we":[47],"report":[48],"case":[50],"49-year-old":[53],"woman":[54],"who":[55],"developed":[56],"19":[58],"months":[59],"into":[60,73],"chemotherapy":[61,102],"Nab-PTX":[63,78],"and":[64,77,79,126],"atezolizumab.":[65],"Improvement":[66],"was":[67,88],"acheieved":[69],"steroid":[71],"injections":[72],"Tenon\u2019s":[75],"sac,":[76],"treatments":[81],"were":[82],"ceased.":[83],"One":[84],"month":[85],"later,":[86],"there":[87],"subjective":[89],"improvement":[90],"in":[91],"her":[92],"symptoms.":[93],"many":[95],"reports":[96],"have":[97],"indicated":[98],"that":[99],"cessation":[100],"successfully":[104],"improved":[105],"CME,":[106],"specific":[108],"for":[110],"established.":[116],"Clinicians":[117],"should":[118],"be":[119],"aware":[120],"ophthalmologic":[123],"effects":[125],"offer":[127],"immediate":[128],"if":[130],"symptoms":[131],"develop.":[132]},"counts_by_year":[],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2024-04-08T00:00:00"}